Table 1

Potential mediators of the CV benefit with liraglutide identified from LEADER

VariableDifference between liraglutide and placebo groups (95% CI)Difference between liraglutide and placebo groups: z score
HbA1c, %ETD: −0.40 (−0.45; −0.34)*−13.5
Body weight, kgETD: −2.3 (−2.5; −2.0)*−16.2
UACRETR: 0.83 (0.78; 0.88)*−6.1
Rate of confirmed hypoglycemia during the trialRate ratio: 0.81 (0.74; 0.88)−4.8
Systolic blood pressure, mmHgETD: −1.2 (−1.9; −0.5)*−3.3
LDL cholesterolETR: 0.98 (0.96; 0.99)*−3.0
Patients who initiated insulin use during the trial, n (%)1,336 (28.8) vs. 2,019 (43.2)
Patients who initiated SU use during the trial, n (%)349 (7.5) vs. 505 (10.8)
  • ETD, estimated treatment difference; ETR, estimated treatment ratio; SU, sulfonylurea.

  • * Change from baseline to 36 months (ETR was used when the data were log-transformed, due to their known distributions).